Addiction Imaging Research Group, Centre for Addiction and Mental Health, Toronto, ON, Canada.
Addiction. 2013 May;108(5):953-63. doi: 10.1111/add.12066. Epub 2013 Jan 3.
Pathological gambling (PG) shares diagnostic features with substance use disorder (SUD), but the neurochemical mechanisms underlying PG are poorly understood. Because dopamine (DA), a neurotransmitter implicated in reward and reinforcement, is probably involved, we used positron emission tomography (PET) to test whether PG is associated with abnormalities in D2 and D3 receptor levels, as observed in SUD.
Case-control study comparing PG to healthy control (HC) subjects.
Academic research imaging centre.
Thirteen non-treatment-seeking males meeting DSM-IV criteria for PG, and 12 matched HC (11 of whom completed PET).
Two PET scans (one with the D3 receptor preferring agonist [11C]-(+)-propyl-hexahydro-naphtho-oxazin (PHNO) and the other with [11C]raclopride) to assess D(2/3) DA receptor availability, and behavioural measures (self-report questionnaires and slot-machine game) to assess subjective effects and relationships to PET measures.
Binding of both radiotracers did not differ between groups in striatum or substantia nigra (SN) (all P > 0.1). Across PG, [11C]-(+)-PHNO binding in SN, where the signal is attributable primarily to D3 receptors, correlated with gambling severity (r = 0.57, P = 0.04) and impulsiveness (r = 0.65, P = 0.03). In HC, [11C]raclopride binding in dorsal striatum correlated inversely with subjective effects of gambling (r = -0.70, P = 0.03) and impulsiveness (r = -0.70, P = 0.03).
Unlike with substance use disorder, there appear to be no marked differences in D2 /D3 levels between healthy subjects and pathological gamblers, suggesting that low receptor availability may not be a necessary feature of addiction. However, relationships between [11C]-(+)-PHNO binding and gambling severity/impulsiveness suggests involvement of the D3 receptor in impulsive/compulsive behaviours.
病理性赌博(PG)与物质使用障碍(SUD)具有相同的诊断特征,但 PG 的神经化学机制尚不清楚。由于多巴胺(DA)是一种与奖励和强化有关的神经递质,可能参与其中,我们使用正电子发射断层扫描(PET)来测试 PG 是否与 SUD 中观察到的 D2 和 D3 受体水平异常有关。
比较 PG 与健康对照(HC)受试者的病例对照研究。
学术研究成像中心。
13 名非治疗寻求的男性,符合 DSM-IV 病理性赌博标准,以及 12 名匹配的 HC(其中 11 名完成了 PET)。
两次 PET 扫描(一次使用 D3 受体优先激动剂 [11C]-(+)-丙基-六氢-萘并恶嗪(PHNO),另一次使用 [11C]raclopride)以评估 D(2/3)DA 受体可用性,以及行为测量(自我报告问卷和老虎机游戏)以评估主观效应和与 PET 测量的关系。
两组纹状体或黑质(SN)的放射性示踪剂结合均无差异(均 P>0.1)。在 PG 中,SN 中的 [11C]-(+)-PHNO 结合与赌博严重程度(r=0.57,P=0.04)和冲动性(r=0.65,P=0.03)相关,SN 中的信号主要归因于 D3 受体。在 HC 中,背侧纹状体中的 [11C]raclopride 结合与赌博的主观效应呈负相关(r=-0.70,P=0.03)和冲动性(r=-0.70,P=0.03)。
与物质使用障碍不同,健康受试者和病理性赌徒之间的 D2 /D3 水平似乎没有明显差异,这表明受体可用性降低可能不是成瘾的必要特征。然而,[11C]-(+)-PHNO 结合与赌博严重程度/冲动性之间的关系表明 D3 受体参与了冲动/强迫行为。